Advertisement

Topics

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

2014-08-27 04:00:43 | BioPortfolio

Summary

The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in elderly patients with major depressive disorder (MDD).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Conditions

Major Depressive Disorder Patients

Intervention

FK949E

Location

Kansai
Japan

Status

Completed

Source

Astellas Pharma Inc

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T04:00:43-0400

Clinical Trials [1574 Associated Clinical Trials listed on BioPortfolio]

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

The purpose of this study is to evaluate the effectiveness, safety and tolerability of an escitalopram combination treatment compared to single treatments, and to placebo in patients with ...

Study Of 323U66 SR In Major Depressive Disorder

This study was designed to evaluate the efficacy and safety in major depressive disorder patients.

PubMed Articles [31980 Associated PubMed Articles listed on BioPortfolio]

TNFAIP3 mRNA Level Is Associated with Psychological Anxiety in Major Depressive Disorder.

Major depressive disorder has been shown to be associated with inflammation and the dysregulation of innate immune responses. Previously, we showed an inverse correlation between the severity of depre...

Clinical characteristics of patients with diagnostic uncertainty of major depressive disorder.

Physicians do not always confidently diagnose psychiatric disorders. The present study was conducted to identify the clinical characteristics of patients in whom a definitive diagnosis of major depres...

Association of Brain Cortical Changes With Relapse in Patients With Major Depressive Disorder.

More than half of all patients with major depressive disorder (MDD) experience a relapse within 2 years after recovery. It is unclear how relapse affects brain morphologic features during the course o...

Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex in depressive episodes of patients with Major Depressive Disorder, Bipolar Disorder I, and Major Depressive with Alcohol Use Disorders.

Dorsolateral prefrontal cortex (DLPFC) is critically involved in mood and alcohol use disorders.

Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.

Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD) are highly comorbid, yet the combined condition has not been subject to any placebo-controlled treatment trials. This study reports a ...

Medical and Biotech [MESH] Definitions

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.

Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.

Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).

An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

More From BioPortfolio on "Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Searches Linking to this Trial